Novavax Inc. shares advanced in the extended session Tuesday after the vaccine developer announced a promising animal study for one of its vaccine candidates. Novavax shares rose 4.5% to $10.63. The company said pregnant guinea pigs given the vaccine candidate transferred protection to their offspring from respiratory syncytial virus, a lead cause of infant infection.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below